ASPREE-D; Aspirin In The Prevention Of Depression In The Elderly
Funder
National Health and Medical Research Council
Funding Amount
$796,784.00
Summary
The ASPREE (ASPirin in Reducing Events in the Elderly) study is a 5 year RCT of aspirin (100mg daily) or placebo in 19,000 healthy people over 70. We aim to augment the existing infrastructure of ASPREE in order to confirm the utility of aspirin for the prevention of depression in the elderly (ASPREE-D). The primary aim of ASPREE-D is to determine if use of low-dose aspirin reduces the incidence of de-novo episodes of depression in healthy individuals over 70 years of age.
Assessing The Benefit Of Low Dose Aspirin In The Prevention Of Severe Sepsis.
Funder
National Health and Medical Research Council
Funding Amount
$391,880.00
Summary
Recent discoveries suggest that low doses of aspirin may save lives in patients with infection by limiting its severity. We will conduct a large-scale primary prevention study using daily low-dose aspirin to explore whether this widely used drug can safely prevent severe infection. This study is made possible by collaborative involvement in an existing Australian and USA funded study called ASPREE. Finding a treatment that helps prevent severe effects and outcomes of infection would be a major h ....Recent discoveries suggest that low doses of aspirin may save lives in patients with infection by limiting its severity. We will conduct a large-scale primary prevention study using daily low-dose aspirin to explore whether this widely used drug can safely prevent severe infection. This study is made possible by collaborative involvement in an existing Australian and USA funded study called ASPREE. Finding a treatment that helps prevent severe effects and outcomes of infection would be a major health advance.Read moreRead less
The SNORE-ASA Study: A Study Of Neurocognitive Outcomes, Radiological And Retinal Effects Of Aspirin In Sleep Apnoea
Funder
National Health and Medical Research Council
Funding Amount
$886,692.00
Summary
Sleep apnoea is very common in the elderly, but it is uncertain whether it leads to a decline in mental abilities as it can in the middle-aged. Apart from fatigue, sleep apnoea also causes mental decline by affecting brain blood supply. This may be preventable with aspirin. We will track 3,000 healthy elderly for 4 years, after testing for sleep apnoea. Half will take aspirin. We predict that mental ability will decline faster with sleep apnoea, and that aspirin will partly reverse this.
Improving The Prevention, Treatment And Management Of Cardiovascular & Chronic Disease In The Community
Funder
National Health and Medical Research Council
Funding Amount
$774,540.00
Summary
The identification, prevention and management of cardiovascular and chronic disease risk factors and understanding impact on clinical outcomes is fundamental to improving health and well-being. The program of work encapsulated in this application utilises modern epidemiological research methods involving large scale clinical trials, registries and epidemiological modelling to advance our understanding and provide new directions for cardiovascular disease prevention and management.
Low Dose Aspirin And Age-related Macular Degeneration: Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,043,189.00
Summary
Age-related macular degeneration (AMD) is a major cause of visual impairment in advanced countries, responsible for nearly half of all legal blindness in Australia. Due to increased life expectancy, the number of people with this progressive late onset disease will double by 2025. Aspirin could prevent or delay the onset of AMD in older persons but its bleeding risk also needs to be considered. This project will determine whether treatment with low dose aspirin reduces incidence or progression o ....Age-related macular degeneration (AMD) is a major cause of visual impairment in advanced countries, responsible for nearly half of all legal blindness in Australia. Due to increased life expectancy, the number of people with this progressive late onset disease will double by 2025. Aspirin could prevent or delay the onset of AMD in older persons but its bleeding risk also needs to be considered. This project will determine whether treatment with low dose aspirin reduces incidence or progression of AMD.Read moreRead less